1P5.F Stock Analysis
1P
Uncovered
PAVmed Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 124 full-time employees. The company went IPO on 2016-07-27. The firm operates through four divisions: Medical Devices, Diagnostics, Digital Health and Emerging Innovations. Its Medical Devices division includes CarpX Minimally Invasive Surgical Device for Carpal Tunnel Syndrome, Infusion Therapy - PortIO Implantable Intraosseous Vascular Access Device and NextFlo Disposable Intravenous Infusion Platform Technology. Its Diagnostics division includes EsoGuard Esophageal DNA Laboratory Developed Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. Its Digital Health division includes Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics. Its Emerging Innovations division includes NextVent ventilators, FlexMO medical circulatory support cannulas, Veris Cardiac Monitor, DisappEAR resorbable pediatric ear tubes and Solys glucose monitoring.